Hypoxia-inducible factor prolyl hydroxylase domain inhibitor may maintain hemoglobin synthesis at lower serum ferritin and transferrin saturation levels than darbepoetin alfa

BACKGROUND: Hypoxia-inducible factor (HIF) prolyl hydroxylase domain inhibitors, which have recently become clinically available for treating renal anemia, are attracting attention for their novel mechanisms of action. METHODS: Relationships of reticulocyte hemoglobin content (CHr), which reflects r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogawa, Chie, Tsuchiya, Ken, Tomosugi, Naohisa, Maeda, Kunimi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213169/
https://www.ncbi.nlm.nih.gov/pubmed/34143801
http://dx.doi.org/10.1371/journal.pone.0252439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213169/
https://www.ncbi.nlm.nih.gov/pubmed/34143801
http://dx.doi.org/10.1371/journal.pone.0252439

Ejemplares similares